Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure

Journal of Medicinal Chemistry

Volumn 56, Issue 13, 2013, Pages 5321-5334

  Zhang, Qingzhi ^a   Milliken, Philip ^b   Kulczynska, Agnieszka ^a   Slawin, Alex M Z ^a   Gordon, Adele ^b   Kirkby, Nicholas S ^b   Webb, David J ^b   Botting, Nigel P ^a   Megson, Ian L ^c  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GUANIDINE DERIVATIVE; N (3 PHENYLPROPYL) N' HYDROXYGUANIDINE HYDROCHLORIDE; N (4 PHENYLBUTYL) N' HYDROXYGUANIDINE HYDROCHLORIDE; N (4 PHENYLETHYL) N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (1 NAPHTHYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (2 METHOXYPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (3 METHOXYPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (4 BROMOPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (4 CHLOROPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (4 FLUOROPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (4 HYDROXYPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (4 METHOXYPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (4 METHYLPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 2 (4 SULFAMOYLPHENYL)ETHYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N 3 CARBOXYPROPYL N METHYLUREA; N BENZYL N' HYDROXYGUANIDINE HYDROCHLORIDE; N N BUTYL N' HYDROXYGUANIDINE; N PHENETHYL N' (4 (GAMMA GLUTAMYLAMINO))BENZYLOXYGUANIDINE; N PHENETHYL N' GLUGGABAOXY N' GLUGABAGUANIDINE; NITRIC OXIDE DONOR; PRODRUG; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ANALYSIS; DRUG DESIGN; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME RELEASE; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY PARENCHYMA; NONHUMAN; RAT; RENAL PROTECTION; VASODILATATION;

ACUTE KIDNEY INJURY; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; GLUTAMIC ACID; GUANIDINES; KIDNEY; MALE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NITRIC OXIDE; NITRIC OXIDE DONORS; PRODRUGS; RATS; RATS, WISTAR; VASODILATOR AGENTS;

EID: 84880140863     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400146r     Document Type: Article

References (75)

1. Groeneveld, A. B.; Tran, D. D.; van der Meulen, J.; Nauta, J. J.; Thijs, L. G. Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome Nephron 1991, 59, 602-610
2. Levy, E. M.; Viscoli, C. M.; Horwitz, R. I. The effect of acute renal failure on mortality. A cohort analysis JAMA, J. Am. Med. Assoc. 1996, 275, 1489-1494
3. Bagshaw, S. M. The long-term outcome after acute renal failure Curr. Opin. Crit. Care 2006, 12, 561-566
4. Hilton, R. Acute renal failure BMJ (Br. Med. J.) 2006, 333, 786-790
5. Gelman, S. The pathophysiology of aortic cross-clamping and unclamping Anesthesiology 1995, 82, 1026-1060
6. Grun, R. P.; Constantinovici, N.; Normand, C.; Lamping, D. L. Costs of dialysis for elderly people in the UK Nephrol., Dial., Transplant. 2003, 18, 2122-2127
7. Chertow, G. M.; Sayegh, M. H.; Allgren, R. L.; Lazarus, J. M. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group Am. J. Med. 1996, 101, 49-53
8. Lassnigg, A.; Donner, E.; Grubhofer, G.; Presterl, E.; Druml, W.; Hiesmayr, M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery J. Am. Soc. Nephrol. 2000, 11, 97-104
9. Bellomo, R.; Chapman, M.; Finfer, S.; Hickling, K.; Myburgh, J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group Lancet 2000, 356, 2139-2143
10. Takala, J.; Meier-Hellmann, A.; Eddleston, J.; Hulstaert, P.; Sramek, V. Effect of dopexamine on outcome after major abdominal surgery: a prospective, randomized, controlled multicenter study. European Multicenter Study Group on Dopexamine in Major Abdominal Surgery Crit. Care Med. 2000, 28, 3417-3423
11. Dehne, M. G.; Klein, T. F.; Muhling, J.; Sablotzki, A.; Osmer, C.; Hempelmann, G. Impairment of renal function after cardiopulmonary bypass is not influenced by dopexamine Renal Failure 2001, 23, 217-230
12. Ralph, C. J.; Tanser, S. J.; Macnaughton, P. D.; Sinclair, D. G. A randomised controlled trial investigating the effects of dopexamine on gastrointestinal function and organ dysfunction in the critically ill Intensive Care Med. 2002, 28, 884-890
13. Kellum, J. A. Use of diuretics in the acute care setting Kidney Int., Suppl. 1998, 66, S67-70
14. Dorman, H. R.; Sondheimer, J. H.; Cadnapaphornchai, P. Mannitol-induced acute renal failure Medicine (Baltimore) 1990, 69, 153-159
15. Mehta, R. L.; Pascual, M. T.; Soroko, S.; Chertow, G. M. Diuretics, mortality, and nonrecovery of renal function in acute renal failure JAMA, J. Am. Med. Assoc. 2002, 288, 2547-2553
16. Ladefoged, S. D.; Andersen, C. B. Calcium channel blockers in kidney transplantation Clin. Transplant. 1994, 8, 128-133
17. Allgren, R. L.; Marbury, T. C.; Rahman, S. N.; Weisberg, L. S.; Fenves, A. Z.; Lafayette, R. A.; Sweet, R. M.; Genter, F. C.; Kurnik, B. R.; Conger, J. D.; Sayegh, M. H. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group N. Engl. J. Med. 1997, 336, 828-834
18. Briguori, C.; Manganelli, F.; Scarpato, P.; Elia, P. P.; Golia, B.; Riviezzo, G.; Lepore, S.; Librera, M.; Villari, B.; Colombo, A.; Ricciardelli, B. Acetylcysteine and contrast agent-associated nephrotoxicity J. Am. Coll. Cardiol. 2002, 40, 298-303
19. Durham, J. D.; Caputo, C.; Dokko, J.; Zaharakis, T.; Pahlavan, M.; Keltz, J.; Dutka, P.; Marzo, K.; Maesaka, J. K.; Fishbane, S. A randomized controlled trial of N -acetylcysteine to prevent contrast nephropathy in cardiac angiography Kidney Int. 2002, 62, 2202-2207
20. Schneider, R.; Raff, U.; Vornberger, N.; Schmidt, M.; Freund, R.; Reber, M.; Schramm, L.; Gambaryan, S.; Wanner, C.; Schmidt, H. H.; Galle, J. l -Arginine counteracts nitric oxide deficiency and improves the recovery phase of ischemic acute renal failure in rats Kidney Int. 2003, 64, 216-225
21. Gryglewski, R. J.; Palmer, R. M.; Moncada, S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor Nature 1986, 320, 454-456
22. MacKenzie, A.; Martin, W. Loss of endothelium-derived nitric oxide in rabbit aorta by oxidant stress: restoration by superoxide dismutase mimetics Br. J. Pharmacol. 1998, 124, 719-728
23. Conger, J.; Robinette, J.; Villar, A.; Raij, L.; Shultz, P. Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats J. Clin. Invest. 1995, 96, 631-638
24. Kakoki, M.; Hirata, Y.; Hayakawa, H.; Suzuki, E.; Nagata, D.; Tojo, A.; Nishimatsu, H.; Nakanishi, N.; Hattori, Y.; Kikuchi, K.; Nagano, T.; Omata, M. Effects of tetrahydrobiopterin on endothelial dysfunction in rats with ischemic acute renal failure J. Am. Soc. Nephrol. 2000, 11, 301-309
25. Chirino, Y. I.; Hernandez-Pando, R.; Pedraza-Chaverri, J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats BMC Pharmacol. 2004, 4, 20
26. Bech, J. N.; Nielsen, C. B.; Pedersen, E. B. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans Am. J. Physiol. 1996, 270, F845-F851
27. Pararajasingam, R.; Weight, S. C.; Bell, P. R.; Nicholson, M. L.; Sayers, R. D. Prevention of renal impairment following aortic cross-clamping by manipulation of the endogenous renal nitric oxide response Eur. J. Vasc. Endovasc. Surg. 2000, 19, 396-399
28. Chintala, M. S.; Chiu, P. J.; Vemulapalli, S.; Watkins, R. W.; Sybertz, E. J. Inhibition of endothelial derived relaxing factor (EDRF) aggravates ischemic acute renal failure in anesthetized rats Naunyn-Schmiedeberg's Arch. Pharmacol. 1993, 348, 305-310
29. Mashiach, E.; Sela, S.; Winaver, J.; Shasha, S. M.; Kristal, B. Renal ischemia-reperfusion injury: contribution of nitric oxide and renal blood flow Nephron 1998, 80, 458-467
30. Matsumura, Y.; Nishiura, M.; Deguchi, S.; Hashimoto, N.; Ogawa, T.; Seo, R. Protective effect of FK409, a spontaneous nitric oxide releaser, on ischemic acute renal failure in rats J. Pharmacol. Exp Ther. 1998, 287, 1084-1091
31. Kurata, H.; Takaoka, M.; Kubo, Y.; Katayama, T.; Tsutsui, H.; Takayama, J.; Matsumura, Y. Nitric Oxide Protects against Ischemic Acute Renal Failure through the Suppression of Renal Endothelin-1 Overproduction J. Cardiovasc. Pharmacol. 2004, 44 (Suppl 1) S455-S458
32. Wilhelm, S. M.; Simonson, M. S.; Robinson, A. V.; Stowe, N. T.; Schulak, J. A. Endothelin up-regulation and localization following renal ischemia and reperfusion Kidney Int. 1999, 55, 1011-1018
33. Miller, M. R.; Megson, I. L. Recent developments in nitric oxide donor drugs Br. J. Pharmacol. 2007, 151, 305-321
34. Renodon-Corniere, A.; Dijols, S.; Perollier, C.; Lefevre-Groboillot, D.; Boucher, J. L.; Attias, R.; Sari, M. A.; Stuehr, D.; Mansuy, D. N -Aryl N ′-hydroxyguanidines, a new class of NO-donors after selective oxidation by nitric oxide synthases: structure-activity relationship J. Med. Chem. 2002, 45, 944-954
35. Mansuy, D.; Boucher, J. L. Alternative nitric oxide-producing substrates for NO synthases Free Radical Biol. Med. 2004, 37, 1105-1121
36. 2 to nitric oxide and citrulline Biochem. Biophys. Res. Commun. 1992, 187, 880-886
37. Boucher, J. L.; Genet, A.; Vadon, S.; Delaforge, M.; Mansuy, D. Formation of nitrogen oxides and citrulline upon oxidation of N -omega-hydroxy- l -arginine by hemeproteins Biochem. Biophys. Res. Commun. 1992, 184, 1158-1164
38. Dambrova, M.; Uhlen, S.; Welch, C. J.; Wikberg, J. E. Identification of an N -hydroxyguanidine reducing activity of xanthine oxidase Eur. J. Biochem. 1998, 257, 178-184
39. Barthelmebs, M.; Caillette, A.; Ehrhardt, J. D.; Velly, J.; Imbs, J. L. Metabolism and vascular effects of gamma- l -glutamyl- l -dopa on the isolated rat kidney Kidney Int. 1990, 37, 1414-1422
40. Wilk, S.; Mizoguchi, H.; Orlowski, M. gamma-Glutamyl dopa: a kidney-specific dopamine precursor J. Pharmacol. Exp. Ther. 1978, 206, 227-232
41. Li Kam Wa, T. C.; Freestone, S.; Samson, R. R.; Johnston, N. R.; Lee, M. R. Renal metabolism and effects of the glutamyl derivatives of l -dopa and 5-hydroxytryptophan in man Clin. Sci. 1996, 91, 177-185
42. Worth, D. P.; Harvey, J. N.; Brown, J.; Lee, M. R. gamma- l -Glutamyl- l -dopa is a dopamine pro-drug, relatively specific for the kidney in normal subjects Clin. Sci. 1985, 69, 207-214
43. Rosalki, S. B. gamma-Glutamyl transpeptidase Adv. Clin. Chem. 1975, 17, 53-107
44. Tate, S. S.; Meister, A. gamma-Glutamyl transpeptidase: catalytic, structural and functional aspects Mol. Cell. Biochem. 1981, 39, 357-368
45. Jia, Q.; Cai, T.; Huang, M.; Li, H.; Xian, M.; Poulos, T. L.; Wang, P. G. Isoform-selective substrates of nitric oxide synthase J. Med. Chem. 2003, 46, 2271-2274
46. Pufahl, R. A.; Nanjappan, P. G.; Woodard, R. W.; Marletta, M. A. Mechanistic probes of N -hydroxylation of l -arginine by the inducible nitric oxide synthase from murine macrophages Biochemistry 1992, 31, 6822-6828
47. Wagenaar, F. L.; Kerwin, J. F. Methodology for the Preparation of N -Guanidino-Modified Arginines and Related Derivatives J. Org. Chem. 1993, 58, 4331-4338
48. Wallace, G. C.; Fukuto, J. M. Synthesis and bioactivity of N -omega-hydroxyarginine: a possible intermediate in the biosynthesis of nitric oxide from arginine J. Med. Chem. 1991, 34, 1746-1748
49. Xian, M.; Fujiwara, N.; Wen, Z.; Cai, T. W.; Kazuma, S.; Janczuk, A. J.; Tang, X. P.; Telyatnikov, V. V.; Zhang, Y. X.; Chen, X. C.; Miyamoto, Y.; Taniguchi, N.; Wang, P. G. Novel substrates for nitric oxide synthases Bioorg. Med. Chem. 2002, 10, 3049-3055
50. Xian, M.; Li, X. P.; Tang, X. P.; Chen, X. C.; Zheng, X. L.; Galligan, J. J.; Kreulen, D. L.; Wang, P. G. N -Hydroxyl derivatives of guanidine based drugs as enzymatic NO donors Bioorg. Med. Chem. Lett. 2001, 11, 2377-2380
51. Caddick, S.; Judd, D. B.; Lewis, A. K. D.; Reich, M. T.; Williams, M. R. V. A generic approach for the catalytic reduction of nitriles Tetrahedron 2003, 59, 5417-5423
52. Zani, B. G.; Bohlen, H. G. Transport of extracellular l -arginine via cationic amino acid transporter is required during in vivo endothelial nitric oxide production American J. Physiol: Heart Circul. Physiol. 2005, 289, H1381-H1390
53. Zharikov, S. I.; Block, E. R. Characterization of l -arginine uptake by plasma membrane vesicles isolated from cultured pulmonary artery endothelial cells Biochim. Biophys. Acta 1998, 1369, 173-183
54. Zhang, Q.; Megson, I.; Botting, N. P.; Webb, D. J.; Kulczynska, A. A new class of NO-donor pro-drugs triggered by [gamma]-glutamyl transpeptidase with potential for reno-selective vasodilatation Chem. Commun. 2012, 49, 1389-1391
55. Leenders, R. G. G.; Gerrits, K. A. A.; Ruijtenbeek, R.; Scheeren, H. W.; Haisma, H. J.; Boven, E. beta-Glucuronyl Carbamate Based Pro-Moieties Designed for Prodrugs in Adept Tetrahedron Lett. 1995, 36, 1701-1704
56. Menard, A.; Castonguay, R.; Lherbet, C.; Rivard, C.; Roupioz, Y.; Keillor, J. W. Nonlinear free energy relationship in the general-acid-catalyzed acylation of rat kidney gamma-glutamyl transpeptidase by a series of gamma-glutamyl anilide substrate analogues Biochemistry 2001, 40, 12678-12685
57. Thompson, G. A.; Meister, A. Interrelationships between Binding-Sites for Amino-Acids, Dipeptides, and Gamma-Glutamyl Donors in Gamma-Glutamyl Transpeptidase J. Biol. Chem. 1977, 252, 6792-6798
58. Tate, S. S.; Meister, A. Gamma-Glutamyl-Transferase Transpeptidase from Kidney Methods Enzymol. 1985, 113, 400-419
59. Elsadek, B.; Graeser, R.; Warnecke, A.; Unger, C.; Saleem, T.; El-Melegy, N.; Madkor, H.; Kratz, F. Optimization of an Albumin-Binding Prodrug of Doxorubicin That Is Cleaved by Prostate-Specific Antigen Med. Chem. Lett. 2010, 1, 234-238
60. Antczak, C.; Bauvois, B.; Monneret, C.; Florent, J. C. A new acivicin prodrug designed for tumor-targeted delivery Bioorg. Med. Chem. 2001, 9, 2843-2848
61. de Groot, F. M. H.; Loos, W. J.; Koekkoek, R.; van Berkom, L. W. A.; Busscher, G. F.; Seelen, A. E.; Albrecht, C.; de Bruijn, P.; Scheeren, H. W. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release J. Org. Chem. 2001, 66, 8815-8830
62. de Groot, F. M. H.; van Berkom, L. W. A.; Scheeren, H. W. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin J. Med. Chem. 2000, 43, 3093-3102
63. Elsadek, B.; Graeser, R.; Esser, N.; Schafer-Obodozie, C.; Abu Ajaj, K.; Unger, C.; Warnecke, A.; Saleem, T.; El-Melegy, N.; Madkor, H.; Kratz, F. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study Eur. J. Cancer 2010, 46, 3434-3444
64. Fossey, C.; Huynh, N. T.; Vu, A. H.; Vidu, A.; Zarafu, I.; Laduree, D.; Schmidt, S.; Laumond, G.; Aubertin, A. M. Synthesis and anti-HIV evaluation of hybrid-type prodrugs conjugating HIV integrase inhibitors with d4t by self-cleavable spacers containing an amino acid residue J. Enzyme Inhib. Med. Chem. 2007, 22, 608-619
65. Greenwald, R. B.; Pendri, A.; Conover, C. D.; Zhao, H.; Choe, Y. H.; Martinez, A.; Shum, K.; Guan, S. Y. Drug delivery systems employing 1,4-or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds J. Med. Chem. 1999, 42, 3657-3667
66. Hay, M. P.; Wilson, W. R.; Denny, W. A. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy Bioorg. Med. Chem. 2005, 13, 4043-4055
67. Muller, I. A.; Kratz, F.; Jung, M.; Warnecke, A. Schiff bases derived from p -aminobenzyl alcohol as trigger groups for pH-dependent prodrug activation Tetrahedron Lett. 2010, 51, 4371-4374
68. Niculescu-Duvaz, D.; Heyes, J.; Springer, C. J. Structure-activity relationship in cationic lipid mediated gene transfection Curr. Med. Chem. 2003, 10, 1233-1261
69. You, H.; Yoon, H. E.; Yoon, J. H.; Ko, H.; Kim, Y. C. Synthesis of pheophorbide-a conjugates with anticancer drugs as potential cancer diagnostic and therapeutic agents Bioorg. Med. Chem. 2011, 19, 5383-5391
70. Lefevre-Groboillot, D.; Boucher, J. L.; Stuehr, D. J.; Mansuy, D. Relationship between the structure of guanidines and N -hydroxyguanidines, their binding to inducible nitric oxide synthase (iNOS) and their iNOS-catalysed oxidation to NO FEBS J. 2005, 272, 3172-3183
71. Slama, P.; Boucher, J. L.; Reglier, M. Aromatic N -hydroxyguanidines as new reduction cosubstrates for dopamine beta-hydroxylase Biochem. Biophys. Res. Commun. 2004, 316, 1081-1087
72. Moali, C.; Boucher, J. L.; Renodon-Corniere, A.; Stuehr, D. J.; Mansuy, D. Oxidations of N (omega)-hydroxyarginine analogues and various N -hydroxyguanidines by NO synthase II: key role of tetrahydrobiopterin in the reaction mechanism and substrate selectivity Chem. Res. Toxicol. 2001, 14, 202-210
73. Beranova, P.; Chalupsky, K.; Kleschyov, A. L.; Schott, C.; Boucher, J. L.; Mansuy, D.; Munzel, T.; Muller, B.; Stoclet, J. C. N -omega-hydroxy- l -arginine homologues and hydroxylamine as nitric oxide-dependent vasorelaxant agents Eur. J. Pharmacol. 2005, 516, 260-267
74. McDonald, K. K.; Rouhani, R.; Handlogten, M. E.; Block, E. R.; Griffith, O. W.; Allison, R. D.; Kilberg, M. S. Inhibition of endothelial cell amino acid transport system y+ by arginine analogs that inhibit nitric oxide synthase Biochim. Biophys. Acta 1997, 1324, 133-141
75. De Mello, G.; Maack, T. Nephron function of the isolated perfused rat kidney Am. J. Physiol. 1976, 231, 1699-1707